denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Regeneron Pharmaceuticals, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Clinical Research, Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Clinical Research, Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events
Friday, December 6, 2024: 7:00 AM-10:00 AM
Room 6A
(San Diego Convention Center)
Chair:
Ajai Chari, MD, University of California, San Francisco
Disclosures:
Chari: Janssen: Research Funding; Antengene: Honoraria; AbbVie; Adaptive; Amgen; Antengene; Bristol Myers Squibb; Forus; Genetech/Roche; GSK; Janssen; Karyopharm; Millenium/Takeda; and Sanofi/Genzyme: Consultancy.
Speaker:
Amrita Y Krishnan, MD, FACP, City of Hope Comprehensive Cancer Center
Disclosures:
Krishnan: Bristol Myers Squibb: Current holder of stock options in a privately-held company; AbbVie; Adaptive; Arcelx; GSK; Janssen; Roche; and Sanofi: Consultancy; Johnson & Johnson: Membership on an entity's Board of Directors or advisory committees; City of Hope National Medical Center: Current Employment.
It's great to have options, and we have more options than ever before for managing heavily pretreated, relapsed/refractory multiple myeloma. The emergence of the new antibodies on the block—bispecifics—has led to notable improvements in outcomes for patients with advanced disease. But more options also means more decisions to be made about patient selection and sequencing. In this 60-minute session, two myeloma experts will discuss all of the practical considerations for integrating bispecific antibodies into the treatment of patients with heavily pretreated, relapsed myeloma. The faculty will both review the clinical evidence and guide you on what it means for your practice. Topics to be addressed include: how bispecific antibodies compare with CAR T-cell therapies, and when each should be used; recommended patient-centered strategies for preventing and managing treatment-related side effects; and how to facilitate collaborative care across clinics and providers to improve our patients' clinical outcomes and lives overall.
Come prepared for a lively session and Q&A on this important clinical topic.
Come prepared for a lively session and Q&A on this important clinical topic.
See more of: Friday Satellite Symposia